Neoadjuvant Chemotherapy, Carboplatin, and Paclitaxel in Pregnancy of a 22-Year Old with Stage IIA2 Cervical Cancer

Page: [316 - 320] Pages: 5

  • * (Excluding Mailing and Handling)

Abstract

Background: Cervical cancer is the second most common cancer found in pregnant women at a young age. Neoadjuvant with carboplatin and paclitaxel is often given to patients with cervical cancer, but the experience of administration during pregnancy is very limited.

Case: A 22-year-old woman was diagnosed with stage IIA2 cervical cancer at 26 weeks gestation. The patient received three medications, including neoadjuvant chemotherapy, carboplatin, and paclitaxel, in three cycles with three weeks intervals at 27 weeks gestation. The patient underwent pregnancy termination with emergency cesarean delivery at 36 weeks of gestation and continued with a hysterectomy radical for 60 days, after which the patient received a chemoradiation adjuvant. Mother and baby were found healthy at one year after the diagnosis.

Conclusion: NACT inhibited progression of the disease and allowed fetal maturity in locally advanced cervical cancer patient at a young age, followed by radical hysterectomy 60 weeks after cesarean section. The combination of carboplatin and paclitaxel seemed feasible and relatively safe for both the mother and the baby.

Keywords: cervical cancer, neoadjuvant chemotherapy, pregnancy, radical hysterectomy, young age

[1]
Gungorduk K, Sahbaz A, Ozdemir A, Gokcu M, Sancı M, Köse MF. Management of cervical cancer during pregnancy. J Obstet Gynaecol 2016; 36(3): 366-71.
[http://dx.doi.org/10.3109/01443615.2015.1065235] [PMID: 26467977]
[2]
Kong Y, Zong L, Yang J, Wu M, Xiang Y. Cervical cancer in women aged 25 years or younger: A retrospective study. Cancer Manag Res 2019; 11: 2051-8.
[http://dx.doi.org/10.2147/CMAR.S195098] [PMID: 30881129]
[3]
Khusen D, Purwoto G, Rachimhadhi T. Pregnancy with cervical cancer. CDK-206 2013; 40(7)
[4]
Bigelow CA, Horowitz NS, Goodman A, Growdon WB, Del Carmen M, Kaimal AJ. Management and outcome of cervical cancer diagnosed in pregnancy. Am J Obstet Gynecol 2017; 216(3): 276.e1-6.
[http://dx.doi.org/10.1016/j.ajog.2016.10.034] [PMID: 27810552]
[5]
Hecking T, Abramian A, Domröse C, et al. Individual management of cervical cancer in pregnancy. Arch Gynecol Obstet 2016; 293(5): 931-9.
[http://dx.doi.org/10.1007/s00404-015-3980-y] [PMID: 26728388]
[6]
Perrone AM, Bovicelli A, D’Andrilli G, Borghese G, Giordano A, De Iaco P. Cervical cancer in pregnancy: Analysis of the literature and innovative approaches. J Cell Physiol 2019; 234(9): 14975-90.
[http://dx.doi.org/10.1002/jcp.28340] [PMID: 30790275]
[7]
Bodog A, Bacalbasa N, Balescu I, Vilcu M, Brezean I, Suciu I. Management of cervical cancer during pregnancy– literature review. Arch Balk Med Union 2018; 53(4): 580-4.
[http://dx.doi.org/10.31688/ABMU.2018.53.4.15]
[8]
Bawono Y, Suryanto S. Does early marriage make women happy?: A phenomenological finding from madurese women. J Educ Health Community Psychol 2019; 8(1): 85-100.
[http://dx.doi.org/10.12928/jehcp.v8i1.12197]
[9]
Louie KS, de Sanjose S, Diaz M, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 2009; 100(7): 1191-7.
[http://dx.doi.org/10.1038/sj.bjc.6604974] [PMID: 19277042]
[10]
Plummer M, Peto J, Franceschi S. International Collaboration of Epidemiological Studies of Cervical Cancer. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 2012; 130(11): 2638-44.
[http://dx.doi.org/10.1002/ijc.26250] [PMID: 21702036]
[11]
Berek JS, Hacker NF. Gynecologic Oncology. (6th ed.), Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins 2015.
[12]
Amant F, Halaska MJ, Fumagalli M, et al. ESGO task force ‘Cancer in Pregnancy’. Gynecologic cancers in pregnancy: Guidelines of a second international consensus meeting. Int J Gynecol Cancer 2014; 24(3): 394-403.
[http://dx.doi.org/10.1097/IGC.0000000000000062] [PMID: 24445819]
[13]
Cordeiro CN, Gemignani ML. Gynecologic malignancies in pregnancy: Balancing fetal risks with oncologic safety. Obstet Gynecol Surv 2017; 72(3): 184-93.
[http://dx.doi.org/10.1097/OGX.0000000000000407] [PMID: 28304416]
[14]
Hoffman BL, Joseph S, Lisa H, et al. Williams Gynecology Study Guide. (2nd ed.), New York: McGraw-Hill Companies Inc. 2012.
[15]
Geijteman ECT, Wensveen CWM, Duvekot JJ, van Zuylen L. A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy. Obstet Gynecol 2014; 124(2 Pt 2) (Suppl. 1): 454-6.
[http://dx.doi.org/10.1097/AOG.0000000000000389] [PMID: 25004323]
[16]
Beharee N, Shi Z, Wu D, Wang J. Diagnosis and treatment of cervical cancer in pregnant women. Cancer Med 2019; 8(12): 5425-30.
[http://dx.doi.org/10.1002/cam4.2435] [PMID: 31385452]
[17]
Li J, Wang LJ, Zhang BZ, Peng YP, Lin ZQ. Neoadjuvant chemotherapy with paclitaxel plus platinum for invasive cervical cancer in pregnancy: Two case report and literature review. Arch Gynecol Obstet 2011; 284(3): 779-83.
[http://dx.doi.org/10.1007/s00404-011-1943-5] [PMID: 21691768]
[18]
Lopez A, Rodriguez J, Estrada E, et al. Neoadjuvant chemotherapy in pregnant patients with cervical cancer: A Latin-American multicenter study. Int J Gynecol Cancer 2021; 31(3): 468-74.
[http://dx.doi.org/10.1136/ijgc-2020-001764] [PMID: 33649015]
[19]
Wang M, Yin Z, Miao J, Wu Y. The fetal outcomes after neoadjuvant platinum and paclitaxel chemotherapy during pregnancy: Analysis of three cases and review of the literature. Arch Gynecol Obstet 2022; 305(1): 49-54.
[http://dx.doi.org/10.1007/s00404-021-06113-8] [PMID: 34115181]